We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Intellia Therapeutics Inc | NASDAQ:NTLA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.21 | 1.00% | 21.19 | 21.18 | 21.20 | 21.4699 | 20.98 | 21.14 | 340,187 | 16:33:21 |
“Intellia has made substantial progress with our science, financing and operations in the first half of 2016,” said Nessan Bermingham, Ph.D., Chief Executive Officer and Founder, Intellia Therapeutics. “Our product focus, therapeutic discovery and development strength, delivery expertise and intellectual property portfolio make Intellia well positioned to advance CRISPR/Cas9 into clinically meaningful genome editing therapeutics for patients with severe and life-threatening diseases.”
Recent Highlights
Second Quarter 2016 Financial Results
As of June 30, 2016, Intellia had $300.7 million in cash and cash equivalents, which includes net proceeds from its initial public offering. Net loss for the second quarter 2016 was $6.9 million, compared to $3.0 million in the same period in 2015.
Collaboration revenue was $4.2 million in the second quarter 2016, compared to $1.4 million in the same period of 2015. The increase in collaboration revenue is primarily attributable to the inclusion of amounts recognized under the Regeneron collaboration in 2016.
Research and development expenses in the second quarter 2016 were $7.4 million, compared to $2.0 million in the same period in 2015. This increase in expenses is primarily attributable to the growth of the Company’s research and development organization to accelerate the development of the CRISPR/Cas9 platform and Intellia’s proprietary and partnered pipeline candidates.
General and administrative expenses were $3.7 million in the second quarter of 2016, compared to $2.8 million for the same period in 2015. The increase in general and administrative expenses is primarily driven by incremental expenses to support the Company’s operations as a new public company, as well as increased headcount-based expenses to support the Company's overall growth.
Research & Development Highlights
Intellia is advancing its pipeline through a risk-mitigated approach focused on sentinel indication development, platform delivery expansion, and preclinical and clinical scale up. The Company is focused on developing the following programs:
Programs | Partnerships | Type of Edit | Delivery | Upcoming Milestones | ||||||||
In Vivo | ||||||||||||
Transthyretin Amyloidosis (ATTR) | Co-developing with Regeneron | Knockout | LNP to Liver | Select 1 to 2 development candidates and advance to IND enabling studies in 2H2017/1H2018 | ||||||||
Alpha-1 Antitrypsin Deficiency (AATD) | Proprietary | Knockout | LNP to Liver | |||||||||
Repair | ||||||||||||
Hepatitis B Virus (HBV) | Proprietary | Knockout | LNP to Liver | |||||||||
Inborn Errors of Metabolism (IEMs) | Proprietary | Knockout | LNP to Liver | |||||||||
Repair | ||||||||||||
Insertion | ||||||||||||
Ex Vivo | ||||||||||||
Hematopoietic Stem Cells (HSCs) | Selectively partnered with Novartis; proprietary | Knockout | Electroporation | First Novartis IND expected to be submitted in 2018 | ||||||||
Repair | ||||||||||||
Insertion | ||||||||||||
CAR T Cells | Partnered with Novartis | Knockout | Electroporation | Advance preclinical development | ||||||||
Insertion |
Upcoming Events
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia was named as one of the top 10 biotech start-ups by Nature Biotechnology. In September 2015, Intellia was named a “Fierce 15” biotech company by FierceBiotech. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements include, but are not limited to, statements regarding our ability to advance CRISPR/Cas9 into therapeutic products for severe and life-threatening diseases; the potential timing and advancement of our clinical trials; the impact of our collaborations with Novartis and Regeneron on our development programs; the potential indications we may pursue, including our sentinel indications; the potential timing of regulatory filings regarding our development programs; and potential commercialization opportunities for product candidates. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of our product candidates will not be successfully developed and commercialized, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies involving current product candidates, the risk that our collaboration with Novartis or Regeneron will not continue or will not be successful, and risks related to our ability to protect and maintain our intellectual property position. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia Therapeutics undertakes no duty to update this information unless required by law.
Intellia Therapeutics, Inc. | |||||||||||||||||||
Consolidated Statements of Operations | |||||||||||||||||||
(unaudited) | |||||||||||||||||||
(in thousands) | |||||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||
2016 | 2015 | 2016 | 2015 | ||||||||||||||||
Collaboration revenue | $ | 4,206 | $ | 1,377 | $ | 5,983 | $ | 2,663 | |||||||||||
Operating expenses: | |||||||||||||||||||
Research and development | 7,422 | 1,966 | 12,647 | 3,337 | |||||||||||||||
General and administrative | 3,729 | 2,833 | 6,975 | 3,943 | |||||||||||||||
Total operating expenses | 11,151 | 4,799 | 19,622 | 7,280 | |||||||||||||||
Operating loss | (6,945 | ) | (3,422 | ) | (13,639 | ) | (4,617 | ) | |||||||||||
Interest income | 46 | - | 51 | - | |||||||||||||||
Loss before income taxes | (6,899 | ) | (3,422 | ) | (13,588 | ) | (4,617 | ) | |||||||||||
Income tax benefit | - | 382 | - | 484 | |||||||||||||||
Net loss | $ | (6,899 | ) | $ | (3,040 | ) | $ | (13,588 | ) | $ | (4,133 | ) |
Intellia Therapeutics, Inc. | ||||||||||
Consolidated Balance Sheets Data | ||||||||||
(unaudited) | ||||||||||
(in thousands) | ||||||||||
June 30, 2016 | December 31, 2015 | |||||||||
Cash and cash equivalents | $ | 300,687 | $ | 75,816 | ||||||
Total assets | 310,624 | 82,139 | ||||||||
Total liabilities | 87,022 | 14,783 | ||||||||
Convertible preferred stock | - | 88,557 | ||||||||
Total stockholders' equity (deficit) | 223,602 | (21,201 | ) |
Media Contact: Jennifer Mound Smoter Chief External Affairs & Communications Officer +1 224-804-4462 jenn.smoter@intelliatx.com Investor Contacts: John Graziano Trout Group 646-378-2942 jgraziano@troutgroup.com Chad Rubin Trout Group 646-378-2947 crubin@troutgroup.com
1 Year Intellia Therapeutics Chart |
1 Month Intellia Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions